Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib in Asian Subjects with Myelofibrosis
NCT02584777Phase 2Withdrawn
- Sponsor
- Takeda
- Start
- Nov 2015
- Primary completion
- Sep 2017
01
Overview
A Phase 2 trial of pacritinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Takeda. Planned start Nov 2015; status: withdrawn.
02
Drugs
pacritinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT02584777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02584777.